Marksans Pharma Profile
Key Indicators
- Authorised Capital ₹ 37.00 Cr
- Paid Up Capital ₹ 5.00 M
- Company Age 24 Year, 2 Months
- Open Charges ₹ 28.12 Cr
- Satisfied Charges ₹ 56.00 Cr
About Marksans Pharma
Marksans Pharma Limited (MPL) is a Public Limited Indian Non-Government Company incorporated in India on 14 December 2000 and has a history of 24 years and two months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 37.00 Cr and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹28.12 Cr. The company has closed loans amounting to ₹56.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24439MH2000PLC130051
- Company No.
130051
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
14 Dec 2000
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Marksans Pharma?
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Marksans Pharma.
Enhance accessibility to Marksans Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Marksans Pharma?
Unlock access to Marksans Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹28.12 Cr
₹56.00 Cr
Charges Breakdown by Lending Institutions
- Canara Bank : 27.00 Cr
- Uti Bank Limited : 1.04 Cr
- Fiat Sundaram Auto Finance Ltd. : 0.09 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Jul 2003 | Canara Bank | ₹27.00 Cr | Open |
| 19 Dec 2002 | Uti Bank Limited | ₹0.40 M | Open |
| 06 Sep 2002 | Fiat Sundaram Auto Finance Ltd. | ₹0.39 M | Open |
| 20 May 2002 | Uti Bank Limited | ₹1.00 Cr | Open |
| 26 Feb 2002 | Fiat Sundaram Auto Finance Ltd. | ₹0.47 M | Open |
How Many Employees Work at Marksans Pharma?
Unlock and access historical data on people associated with Marksans Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Marksans Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Marksans Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
